News

Stay up to date with the latest developments from OrchestratePharma.

January 13, 2022

OP2101 - OrchestratePharma initiates phase 1 bioavailability study with IVRS

OrchestratePharma has initiated its phase 1 bioavailability study with IVRS, marking a significant milestone in the development of OP2101 — our lead topical fexofenadine candidate for atopic dermatitis.

November 11, 2021

OrchestratePharma signs agreement with Cellix Bioscience for CSU

OrchestratePharma has signed an agreement with Cellix Bioscience to advance the clinical development of fexofenadine-based treatments for chronic spontaneous urticaria (CSU).